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SUMMARY 
The Receiver Operating Characteristic (ROC) curve and the Area Under the Curve (AUC) of the ROC 
curve are widely used to compare the performance of diagnostic and prognostic assays.  The ROC 
curve has the advantage that it is independent of disease prevalence.  However, in this note we 
remind readers that the performance of an assay upon translation to the clinic is critically dependent 
upon that very same prevalence.  Without an understanding of prevalence in the test population, 
even robust bioassays with excellent ROC characteristics may perform poorly in the clinic.  Instead, 
simple plots of candidate assay performance as a function of prevalence rate give a more realistic 
understanding of the likely real-world performance and a greater understanding of the likely impact 
of variation in that prevalence on translational performance in the clinic.   
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The Receiver Operating Characteristic (ROC) curve is a widely used tool to evaluate diagnostic and 1 
prognostic biomarker performance1,2,3.  The ROC curve compares the sensitivity and specificity of a 2 
candidate biomarker for a range of potential cut-off values for a biomarker assay.  One of the 3 
perceived advantages of the ROC curve is that it is independent of the prevalence of the disease and 4 
captures the two key misclassification errors – false positive errors and false negative errors – as a 5 
function of biomarker cut-offs.   6 
However, while the ROC curve is independent of the prevalence rate, the translational performance 7 
of a biomarker test in the clinic is critically dependent upon that very same prevalence rate4,5.  For 8 
example, the “10-90-50 Rule” states that: 9 
• for a disease with a prevalence of 10%, and 10 
• an assay with both sensitivity and specificity greater than 90% (ROC AUC > 0.90),  11 
• means that 50% of patients testing positive are false alarms. 12 
And if the prevalence of the disease is less than 10% then most of our positive diagnostic tests will be 13 
false alarms – see Figure 1.   14 
While ROC AUCs and alternatives attempt to capture assay performance independently of 15 
prevalence, in this note we argue that there are advantages in looking at the robustness of a 16 
candidate assay to variation in those prevalence rates.  Understanding how an assay performs across 17 
a range of values for the functional prevalence is critical in the clinic.    18 
To begin with, there is often uncertainty surrounding the estimate of prevalence in the first 19 
place.  Then, once the test is moved into the clinic, this is compounded by the fact that the 20 
prevalence rates vary depending upon how the patients are selected for testing.  And, even 21 
following adoption of the test, the test may be used for groups of patients for whom the prevalence 22 
is rather less than that in the original test population, making the test virtually 23 
worthless. Translational performance is a function of both the ‘true’ disease prevalence and the 24 
clinical selection process for testing4,5.    25 
Rather than ignore prevalence, simple plots of candidate assay performance as a function of 26 
prevalence rate give a more realistic understanding of the likely real-world performance in the clinic, 27 
and a greater understanding of the likely impact of variation in that prevalence on translational 28 
performance in the clinic – see Figure 1B.  Plotting the misclassification rates – False Alarms and 29 
Missed Diagnoses – as a function of possible prevalence rates allows us to focus on misclassification 30 
costs.   31 
In Figure 2, we give a worked example showing prevalence plots for the promising mast cell 32 
activation test for IgE-mediated food allergy6. The sensitivity and specificity of this test are an 33 
impressive 97% and 92% respectively, with a ROC AUC of 0.99 (95% CI: 0.96, 1.00).  While the 34 
number of patients with food allergies who are missed by the assay is reassuringly low, the number 35 
of patients without the disease testing positive is likely to be high, given an estimated prevalence in 36 
the UK of just 6%.  This may, or may not, be acceptable.  In real life, the relative costs associated 37 
with false alarms and missed diagnoses are likely to be very different and must be assessed prior to 38 
the test entering the clinic: a false alarm may simply mean a patient is subjected to further testing; a 39 
missed diagnosis may mean the patient dies.   40 
Prevalence plots focus reviewers on misclassification rates, misclassification costs, and how the 41 
assay will translate to the clinic. Without thoughtful consideration of prevalence rates and the 42 
relative costs of misclassification errors, it is easy to 1) overstate the potential value of a candidate 43 
biomarker, 2) generate unrealistic expectations of that candidate, 3) incur unnecessary trial costs in 44 
evaluating that candidate, 4) incur opportunity costs in denying patients access to better diagnostic 45 
tests.    46 
We provide an Excel workbook permitting readers to estimate Missed Cases, False Alarms and other 47 
key assay characteristics including prevalence plots for their assays for any given sensitivity and 48 
specificity.49 
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Figure 1:  The 10-90-50 Rule.  While the ROC AUC for our candidate biomarker looks promising 
(A) giving an assay with both sensitivity and specificity of 90%, the performance of the assay in 
the clinic depends critically on the prevalence of the disease (B).  The false positive and false 
negative rates are both 10%, but if the prevalence of the disease in the test population is 10% 
then 50% of all positive tests will be false alarms. The false alarm rate depends critically upon 
the prevalence in the test population. Plotting test performance as a function of prevalence 
gives a more realistic understanding of likely performance in the clinic.  See text for details.  
 
  
 
 
 
 
 
 
  
Figure 2:  Prevalence plots for the mast cell activation assay.  While the assay looks promising - with a 
sensitivity of 97%, specificity of 92% and a ROC AUC of 0.99 - translation to the clinic depends critically 
upon the prevalence in the test population. As the prevalence increases, the percentage of missed cases 
increase and the false alarms decrease.  If the prevalence rate is zero then any positive test results are false 
positives and the false alarm rate is 100%. If the prevalence rate is 100% then any negative tests are false 
negatives and the missed case rate is 100%.  The vertical line shows the estimated prevalence of IgE-
mediated food allergy at 6%.  At this rate, while 56% of all positive tests will be false alarms, just 17 tests 
will be needed to identify each new case of IgE-mediated food allergy – see Supplementary Excel 
Workbook. 
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